Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles. Potential side effects include anaphylaxis and infusion-related reactions such as rash and diarrhea. Gilead and Merck will share global development and commercialization costs 60% and 40%, respectively, while having an equal share of the therapy's sales until the revenue crosses certain milestones.
Gilead has reported greater than 2% of the global market share.
( z0 report :ARG0 ( z1 person :name ( z2 name :op "Gilead" ) ) :rel ( z3 more-than :ARG1-of ( z4 include :ARG2 ( z5 share :mod ( z6 market :location ( z7 globe ) ) ) ) :op ( z8 percentage-entity :value 2 ) ) )
(z0 / report-01
    :ARG0 (z1 / person
              :name (z2 / name
                        :op1 "Gilead"))
    :rel (z3 / more-than
             :ARG1-of (z4 / include-91
                          :ARG2 (z5 / share
                                    :mod (z6 / market
                                             :location (z7 / globe))))
             :op1 (z8 / percentage-entity
                      :value 2)))
Gilead has reported greater than 2 % of the global market share .
z1 :name z2
z2 :op1 1
z0 :ARG0 z1
z8 :value 0
z3 :op1 z8
z3 :ARG1-of z4
z6 :location z7
z5 :mod z6
z4 :ARG2 z5
z0 :rel z3